Author

R. Derua

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Biochemistry· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 3 Approach:biophysical modeling· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

E. Waelkens· 2 shared A. D. Garg· 1 shared A. D. Vincent· 1 shared A. Kotsubei· 1 shared A. Sablina· 1 shared B. Knoops· 1 shared C. Cokelaere· 1 shared C. Costa· 1 shared

Activity by Year

2018-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 8 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

E. Waelkens

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

TIPRL1 and its ATM-dependent phosphorylation promote radiotherapy resistance in head and neck cancer

V. Janssens, C. Cokelaere, R. Dok, E. Cortesi, P. Zhao, A. Sablina, S. Nuyts, R. Derua

This study identifies TIPRL1 and its ATM-dependent phosphorylation as contributors to radiotherapy resistance in head and neck cancer by modulating DNA damage response.

bioRxiv · Aug 30, 2023Cancer Biology

Peroxisome-derived hydrogen peroxide can modulate the sulfenylation profiles of key redox signaling proteins

C. Lismont, I. Revenco, H. Li, C. Costa, L. Lenaerts, M. Hussein, J. De Bie, B. Knoops, P. P. Van Veldhoven, R. Derua, M. Fransen

This study identifies peroxisome-derived H2O2 targets and shows their sulfenylation kinetics vary across compartments and protein families.

bioRxiv · Oct 8, 2021Cell Biology

The IRE1 Inhibitor KIRA6 Curtails The Inflammatory Trait Of Immunogenic Anticancer Treatments By Targeting HSP60 Independent Of IRE1

N. Rufo, D. Korovesis, S. van Eygen, R. Derua, A. D. Garg, F. Finotello, M. Vara Perez, J. Rozanc, M. Dewaele, P. A. de Witte, L. Alexopoulos, S. Janssens, L. Sinkkonen, T. Sauter, S. H. L. Verhelst, P. Agostinis

The paper shows KIRA6 reduces inflammation from immunogenic cancer treatments by targeting HSP60, not through IRE1 inhibition.

bioRxiv · Dec 24, 2020 · PreprintCancer Biology

Lipidomic profiling of clinical prostate cancer reveals targetable alterations in lipid composition

L. M. Butler, C. Y. Mah, J. Machiels, A. D. Vincent, S. Irani, S. Mutuku, X. Spotbeen, M. Bagadi, D. Waltregny, M. Moldovan, J. Dehairs, F. Vanderhoydonc, K. Bloch, R. Das, J. Stahl, , J. V. Swinnen

The paper profiles lipidomes in prostate cancer tissues and identifies targetable lipid alterations linked to AR signaling and therapeutic response.

bioRxiv · Oct 27, 2020Cancer Biology

Structures of the heart specific SERCA2a Ca2+-ATPase

P. Nissen, J. De Raeymaecker, A. Kotsubei, N. D. Drachmann, R. Derua, S. Smaardijk, J. L. Andersen, I. Vandecaetsbeek, J. Chen, M. De Mayer, E. Waelkens, C. E. Olesen, P. Vangheluwe

The paper presents the first crystal structures of SERCA2a, revealing structural and regulatory differences from SERCA1a and providing insights into its function in cardiac muscle.

bioRxiv · Jun 12, 2018Biochemistry